Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
暂无分享,去创建一个
W. Choi | J. Winter | K. Dybkær | M. Piris | G. Bhagat | Y. Zu | K. Young | Z. Xu-Monette | L. Medeiros | K. Richards | A. Tzankov | M. Møller | J. Huh | G. Manyam | S. Montes-Moreno | F. Bertoni | C. Visco | E. Hsi | M. Ponzoni | A. Ferreri | J. V. van Krieken | Jiayu Chen | A. Chiu | Ling Li | A. Orazi | Xiaoying Zhao | C. Ok | J. Farnen
[1] O. Coqueret,et al. Opposite regulation of Myc and p21waf1 transcription by STAT3 proteins. , 2014, The Journal of Biological Chemistry.
[2] P. Qiu,et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells , 2013, Oncotarget.
[3] L. Staudt,et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] W. Choi,et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[5] Y. Oki,et al. Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma , 2013, Clinical Cancer Research.
[6] J. Briones,et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.
[7] W. Choi,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[8] H. Maehr,et al. Targeting CD44-STAT3 Signaling by Gemini Vitamin D Analog Leads to Inhibition of Invasion in Basal-Like Breast Cancer , 2013, PloS one.
[9] Hua Yu,et al. Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer , 2013, PloS one.
[10] T. Witzig,et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. , 2012, Blood.
[11] W. Choi,et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.
[12] K. Dybkær,et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.
[13] J. Cultrera,et al. Diffuse large B-cell lymphoma: current strategies and future directions. , 2012, Cancer control : journal of the Moffitt Cancer Center.
[14] M. Gupta,et al. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy , 2012, Leukemia.
[15] S. Mustjoki,et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.
[16] Li Lin,et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.
[17] Gang Wu,et al. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis , 2011, Medical oncology.
[18] Jun Zhu,et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma , 2011, Journal of hematology & oncology.
[19] Hua Yu,et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. , 2011, Cancer research.
[20] M. Karin,et al. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.
[21] Hua Yu,et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.
[22] S. Pileri,et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas , 2009, Modern Pathology.
[23] A. Mansoor,et al. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation , 2009, Leukemia & lymphoma.
[24] L. Staudt,et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. , 2008, Blood.
[25] W. Gerald,et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.
[26] G. Cattoretti,et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. , 2007, Blood.
[27] G. Stark,et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.
[28] W. Gerald,et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.
[29] A. Fersht,et al. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs , 2006, Proceedings of the National Academy of Sciences.
[30] K. Aldape,et al. Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.
[31] E. Verdin,et al. NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.
[32] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Jianyuan Luo,et al. Activation of Stat3 Sequence-specific DNA Binding and Transcription by p300/CREB-binding Protein-mediated Acetylation* , 2005, Journal of Biological Chemistry.
[34] B. Barton,et al. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. , 2004, Molecular cancer therapeutics.
[35] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[36] Nicola Gebbia,et al. STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.
[37] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[38] Rolf Rossaint,et al. Activation of STAT3 by IL-6 and IL-10 in Primary Human Macrophages Is Differentially Modulated by Suppressor of Cytokine Signaling 3 1 , 2003, The Journal of Immunology.
[39] S. Bhattacharya,et al. Regulation of Stat3 nuclear export. , 2003, The Journal of clinical investigation.
[40] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[41] T. Yeatman,et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[42] J Diebold,et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.
[43] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[44] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[45] T. Hirano,et al. Stat3 Is Required for the Gp130-mediated Full Activation of the C-myc Gene , 1999 .
[46] T. Hirano,et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. , 1996, Immunity.
[47] J. Darnell,et al. Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.
[48] W. Choi,et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.
[49] K. Dybkær,et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2014, Leukemia.
[50] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.